Blueprint Medicines Corporation (BPMC): Price and Financial Metrics

Blueprint Medicines Corporation (BPMC): $94.86

0.07 (+0.07%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add BPMC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#245 of 365

in industry

BPMC Price/Volume Stats

Current price $94.86 52-week high $101.00
Prev. close $94.79 52-week low $41.54
Day low $93.50 Volume 659,200
Day high $95.98 Avg. volume 811,326
50-day MA $86.15 Dividend yield N/A
200-day MA $67.48 Market Cap 5.81B

BPMC Stock Price Chart Interactive Chart >

BPMC POWR Grades

  • BPMC scores best on the Sentiment dimension, with a Sentiment rank ahead of 56.88% of US stocks.
  • BPMC's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • BPMC's current lowest rank is in the Stability metric (where it is better than 5.9% of US stocks).

BPMC Stock Summary

  • BPMC's price/sales ratio is 24.95; that's higher than the P/S ratio of 94.94% of US stocks.
  • With a year-over-year growth in debt of 36.92%, BLUEPRINT MEDICINES CORP's debt growth rate surpasses 84.06% of about US stocks.
  • As for revenue growth, note that BPMC's revenue has grown -20.59% over the past 12 months; that beats the revenue growth of merely 13.36% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BLUEPRINT MEDICINES CORP, a group of peers worth examining would be DCPH, FULC, ADVM, MTNB, and SABS.
  • BPMC's SEC filings can be seen here. And to visit BLUEPRINT MEDICINES CORP's official web site, go to www.blueprintmedicines.com.

BPMC Valuation Summary

  • In comparison to the median Healthcare stock, BPMC's price/sales ratio is 1077.27% higher, now standing at 25.9.
  • Over the past 106 months, BPMC's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for BPMC.

Stock Date P/S P/B P/E EV/EBIT
BPMC 2023-12-29 25.9 27.7 -10.1 -11.1
BPMC 2023-12-28 25.7 27.4 -10.0 -11.0
BPMC 2023-12-27 26.1 27.9 -10.2 -11.2
BPMC 2023-12-26 25.5 27.2 -10.0 -10.9
BPMC 2023-12-22 25.0 26.7 -9.7 -10.7
BPMC 2023-12-21 24.2 25.8 -9.4 -10.4

BPMC Growth Metrics

    The 2 year price growth rate now stands at 6.53%.
  • The 4 year cash and equivalents growth rate now stands at 560.04%.
  • Its 2 year net income to common stockholders growth rate is now at -75.19%.
BPMC's revenue has moved up $205,764,000 over the prior 33 months.

The table below shows BPMC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 272.276 -394.986 -717.557
2022-06-30 230.487 -360.692 -701.635
2022-03-31 221.235 -305.601 -650.37
2021-12-31 180.08 -298.653 -644.085
2021-09-30 107.165 -309.338 -411.067
2021-06-30 828.095 408.584 340.152

BPMC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BPMC has a Quality Grade of C, ranking ahead of 33.2% of graded US stocks.
  • BPMC's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
  • OTLC, SGEN, and OCGN are the stocks whose asset turnover ratios are most correlated with BPMC.

The table below shows BPMC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.067 0.871 -0.440
2021-06-30 0.512 0.992 0.352
2021-03-31 0.566 0.999 0.382
2020-12-31 0.634 0.999 0.411
2020-09-30 0.812 1.000 0.485
2020-06-30 0.095 0.998 -0.729

BPMC Price Target

For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $119.69 Average Broker Recommendation 1.47 (Moderate Buy)

Blueprint Medicines Corporation (BPMC) Company Bio


Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.


BPMC Latest News Stream


Event/Time News Detail
Loading, please wait...

BPMC Latest Social Stream


Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PT (1:30 p.m. ET).

Yahoo | December 18, 2023

Blueprint Medicines Corporation's (NASDAQ:BPMC) 38% Price Boost Is Out Of Tune With Revenues

Blueprint Medicines Corporation ( NASDAQ:BPMC ) shares have continued their recent momentum with a 38% gain in the last...

Yahoo | December 18, 2023

Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (NASDAQ:BPMC) has recently witnessed a notable insider sell by Director Jeffrey Albers, who disposed of 5,000 shares of the company's stock.

Yahoo | December 14, 2023

Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

TalkMarkets.com | December 13, 2023

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Yahoo | December 12, 2023

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo -0.62%
3-mo 2.84%
6-mo 88.89%
1-year 114.18%
3-year 1.70%
5-year 18.50%
YTD 2.84%
2023 110.55%
2022 -59.10%
2021 -4.49%
2020 40.00%
2019 48.60%

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!